SQSTM1 and cancer: In contrast, in bulk analysis of the MDA-MB-231 and cisplatin-treated PACCs, most of the proteins showed similar abundances at the same injection amount (1.0 μg) level; however, we found more than two-fold decrease in PACC compared to MDA-MB-231 cancer cells for p62/SQSTM1, HIST1H4A and HIST1H1E.